Skip to main content

FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Fifth Consecutive Year

Written by Customer Service on . Posted in Public Companies.

MISSISSAUGA, Ontario, May 01, 2020 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fifth consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian pharmacists and physicians.
The 2020 Survey on OTC Counselling & Recommendations was conducted by Ensemble IQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHealthcareNetwork.ca and ProfessionSanté.ca. This annual online survey was conducted between October 2019 and January 2020 with Canadian retail pharmacists and physicians. In total, 1,426 surveys were completed by Canadian pharmacists and 654 surveys were completed by Canadian physicians. FeraMAX® was named as the most recommended iron supplement brand nationally both by pharmacists and physicians.  The percentage of recommendations was 48% among national pharmacists and 47% among national physicians.  This is a significant achievement, considering the competitive iron supplement landscape.  “We are very proud that FeraMAX® has maintained its #1 ranking among Canadian healthcare professionals for a fifth consecutive year,” commented Mr. René Goehrum, President and CEO of BioSyent.  “We are grateful for the ongoing support of these healthcare professionals in continuing to recommend FeraMAX® to their patients.  We look forward to continuing to build on the success of FeraMAX® in Canada.”    About FeraMAX®FeraMAX® 150 is an oral iron supplement indicated for the prevention and treatment of iron deficiency anaemia. This non-ionic polysaccharide-iron complex formulation offers several benefits compared to conventional iron salt supplements and is well-tolerated.  FeraMAX® is Vegan Certified and provides an iron therapy option for vegans, vegetarians, and patients with other dietary restrictions. FeraMAX® is also recognized by the Society of Obstetricians and Gynaecologists of Canada.   FeraMAX® Powder, based upon the same innovative non-ionic polysaccharide-iron complex technology found in FeraMAX® 150, is available in a pleasant tasting, dissolvable powder for pediatric patients.For more information on FeraMAX®, please visit www.feramax.com.About BioSyent Inc.Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.As of the date of this press release, the Company has 12,989,170 common shares outstanding.For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.This press release may contain information or statements that are forward-looking.  The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements.  Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.For further information please contact:Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.